Clinical ShowCase™: A Mysterious Metabolic Disorder

Release Date: March 30, 2020
Expiration Date: March 30, 2021

Activity Overview

This online activity is designed to provide concise and easy-to-digest education in an engaging and interactive case-based format on recognizing the signs and symptoms of long-chain fatty acid oxidation disorders (LC-FAOD) and choosing the most appropriate therapy based on the clinical scenario. The engaging multimedia format of this program includes interactive clinical decision points with explanations at the end of the activity, and an evidence-based review supporting the teaching points covered in the case.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Ultragenyx Pharmaceutical Inc.

Target Audience

This educational activity is directed toward pediatricians, primary care physicians, endocrinologists, nurse practitioners, physician assistants, and other health care professionals involved in the care of patients with metabolic disorders.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Evaluate signs and symptoms of FAOD to differentially diagnose it from other metabolic disorders
• Select next steps in care for patients with FAOD regarding current and emerging treatment options

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

J. Lawrence Merritt II, MD
Program Director
Medical Biochemical Genetics Fellowship
Associate Professor, Biochemical Genetics
Division of Genetic Medicine
Department of Pediatrics
University of Washington School of Medicine
Seattle, WA

Disclosures: Grant Research Support: National Institutes of Health; O’Malley Family Foundation; Horizon Pharma; Cytonet; Sanofi Genzyme; Aeglea BioTherapeutics, Inc; Moderna Therapeutics, Ultragenyx Pharmaceutical; Shire Pharmaceuticals; BioMarin Pharmaceutical Inc; Kaleido Biosciences; Translate Bio; Consulting Fees and Honoraria: Sanofi Genzyme, Horizon Pharma, Asklepios Biopharmaceutical, Inc.

Sheri A. Poskanzer, MD
Clinical Genetics and Genomics
Seattle, WA

Disclosures: no relevant financial relationships with commercial interests to disclose.

The staff Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.